(Total Views: 576)
Posted On: 11/04/2022 5:13:12 PM
Post# of 145247
![Avatar](https://investorshangout.com/images/ProfileImages/424989898_3046_Avatar jpeg2.jpg)
Huh. Who knew that there's a "formal dispute" process to the FDA.
I assume that the FDA is in charge of the appeal. I bet THAT's not biased in favor of the FDA, not one bit.
I assume that the FDA is in charge of the appeal. I bet THAT's not biased in favor of the FDA, not one bit.
Quote:
Akebia Therapeutics has elected to not sit idly by after regulators rejected its chronic kidney disease med vadadustat earlier in the year, submitting a formal dispute request to the FDA.
In a complete response letter back in March, the agency had flagged safety concerns related to adjudicated blood clots and drug-induced liver injury. But Akebia pushed back last month, sending across a formal dispute request that defended vadadustat as a potential treatment for anemia due to chronic kidney disease in adult patients on dialysis.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)